Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis

BACKGROUND: Choosing optimal biologic and targeted synthetic DMARD (b/tsDMARD) regimens for individual RA patients can be challenging. This study used electronic health records and linked genotyping data from two large biobanks to investigate genetic factors associated with RA treatment patterns. METHODS: We identified RA patients initiating b/tsDMARDs and with available genotyping data in the Million Veteran Program (MVP) and Mass General Brigham (MGB) Biobank. We used mixture Markov modeling to identify patterns of b/tsDMARD use. We calculated inflammatory arthritis genetic risk scores (GRS) for RA, spondyloarthritis, psoriatic arthritis, lupus, and gout and examined the association of the GRS with b/tsDMARD treatment pattern using logistic regression. RESULTS: Among 2,454 RA patients in the MVP and 461 patients in the MGB Biobank, we identified common patterns of b/tsDMARD use: TNFi persisters, TNFi to abatacept, and multi-bDMARD cyclers. In the meta-analysis, a higher RA GRS was associated with higher odds of belonging to the TNFi to abatacept group (OR 1.129 95%CI 1.008-1.264 per GRS standard deviation) and multi-b/tsDMARD cycling (1.137 95%CI 1.056-1.223) compared to TNFi-persisters. The spondyloarthritis GRS was associated with a lower odds belonging to multi-b/tsDMARD (OR 0.824 95%CI 0.762-0.892) or TNFi to abatacept (OR 0.883 95%CI 0.786-0.992) patterns compared to TNFi persisters. CONCLUSIONS: Among patients with RA, we observed common patterns of b/tsDMARD use in two separate healthcare systems. Moreover, these patterns had different underlying genetic associations. Higher RA GRS was associated with lower odds of TNFi persistence, while a higher SpA GRS was associated with higher odds of TNFi persistence.

Authors

Institutions

Publication Details

Journal
Arthritis & Rheumatology
Published
2026-11-20
DOI
https://doi.org/10.1002/art.70399
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis

Sara Morini, Rachel Knevel, Katherine P. Liao, Rahul Sangar et al.
2 links
Arthritis & Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis

Sara Morini, Rachel Knevel, Katherine P. Liao, Rahul Sangar, Gregory C McDermott, Andrew Cagan, Jing Cui, Soumya Raychaudhuri, Rui Duan, Daniel Posner, Rachael Matty, Elizabeth Karlson, Xin Xiong, Lauren Costa, Kelly Cho, Yuk‐Lam Ho, Mary Jeffway, Vidul Panickan, Tianxi Cai
article en

Abstract

BACKGROUND: Choosing optimal biologic and targeted synthetic DMARD (b/tsDMARD) regimens for individual RA patients can be challenging. This study used electronic health records and linked genotyping data from two large biobanks to investigate genetic factors associated with RA treatment patterns. METHODS: We identified RA patients initiating b/tsDMARDs and with available genotyping data in the Million Veteran Program (MVP) and Mass General Brigham (MGB) Biobank. We used mixture Markov modeling to identify patterns of b/tsDMARD use. We calculated inflammatory arthritis genetic risk scores (GRS) for RA, spondyloarthritis, psoriatic arthritis, lupus, and gout and examined the association of the GRS with b/tsDMARD treatment pattern using logistic regression. RESULTS: Among 2,454 RA patients in the MVP and 461 patients in the MGB Biobank, we identified common patterns of b/tsDMARD use: TNFi persisters, TNFi to abatacept, and multi-bDMARD cyclers. In the meta-analysis, a higher RA GRS was associated with higher odds of belonging to the TNFi to abatacept group (OR 1.129 95%CI 1.008-1.264 per GRS standard deviation) and multi-b/tsDMARD cycling (1.137 95%CI 1.056-1.223) compared to TNFi-persisters. The spondyloarthritis GRS was associated with a lower odds belonging to multi-b/tsDMARD (OR 0.824 95%CI 0.762-0.892) or TNFi to abatacept (OR 0.883 95%CI 0.786-0.992) patterns compared to TNFi persisters. CONCLUSIONS: Among patients with RA, we observed common patterns of b/tsDMARD use in two separate healthcare systems. Moreover, these patterns had different underlying genetic associations. Higher RA GRS was associated with lower odds of TNFi persistence, while a higher SpA GRS was associated with higher odds of TNFi persistence.

Arthritis & Rheumatology
Brigham and Women's Hospital (US), Harvard University (US), VA Boston Healthcare System (US)
Rheumatology Research Foundation, Office of Research and Development, National Institutes of Health
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon